Newsletter | May 1, 2024

05.01.24 -- Nothing To See Here! Just Big Pharma Investments In China

SPONSOR

Showcasing state-of-the-art facilities and cutting-edge equipment driving the API manufacturing process - Outsourced Pharma Capacity Update’s new PARTNER WEEK offers an extended schedule grouped by capability including a new Small Molecule API & HPAPI Development session. Register today for this digital event happening May 22nd.

FEATURED EDITORIAL

Nothing To See Here! Just Big Pharma Investments In China

WuXi AppTec assists U.S.-based biotechs to develop and supply drugs to U.S. patients. Western-based Pharma assists the development of China's industry, the China Communist Party (CCP) by extension, and patients there. Guess which is under assault? Chief Editor Louis Garguilo tries to figure it all out.

FDA Publishes Final Guidance On Reporting Listed Drug Amounts

Despite earlier efforts to shore up the U.S. drug supply chain, COVID-19 still brought shortages. A new FDA reporting system aims to reduce future supply risks.

INDUSTRY INSIGHTS

Integrating Early Development With Clinical Supply

In the era of seamless development, reducing time to the clinic and getting rapid approval is key. An integrated approach can accelerate timelines, avoid communication pitfalls, and improve outcomes.

Optimizing Pediatric Product Development For Commercialization Success

Ensuring medication adherence in pediatric patients presents challenges for pharmacotherapy. Explore various dosing solutions and learn how to streamline your pediatric development journey.

Continuous Flow Techniques For Fine Chemical Manufacturing

Discover the advantages and challenges of continuous flow processes and the concept of mini-monoplant technology, along with examples that demonstrate the versatility of continuous processing.

Investing In Capacity – API Commercial Manufacturing

A pharma company sought a CMO partner with commercial manufacturing capabilities and expertise as well as exemplary quality systems to find a cost-effective process to produce the API for a new drug.

SPONSOR

To support fast-track clinical programs, CMC professionals in early-stage biotechs find themselves behind the eight ball. Start-ups overestimate their understanding of the scope, complexity, and impact of CMC. They then rely on CDMOs to assist with arbitrarily decided clinical start dates. Outsourced Pharma Live is here to offer remedies for all this pushing a program into and through the clinic, and for effective utilization of CMC operations. Register today!

SOLUTIONS

End-To-End Ophthalmic Drug Development Solutions

As a leading partner in ocular therapy, Altasciences is at the forefront of ophthalmic drug development. Our integrated CRO/CDMO solutions support programs from lead candidate selection to market.

Global Contract Manufacturing Capabilities

With 10 state-of-the-art facilities in North America and Europe, AbbVie Contract Manufacturing offers a wide range of global contract manufacturing capabilities.

OUTSOURCED PHARMA CAPACITY UPDATE

Find Your New CDMO At Outsourced Pharma Capacity Update

CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capacities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs.

Connect With Outsourced Pharma: